Q Fever News and Research

RSS

Morphotek announces preliminary data from Phase II trial of farletuzumab

Morphotek(R), Inc., a subsidiary of Eisai Corporation of North America, today announced preliminary data from a Phase II trial evaluating the safety and efficacy of farletuzumab in platinum-sensitive epithelial ovarian cancer subjects experiencing their first relapse. Farletuzumab (MORAb-003) is a humanized monoclonal antibody that targets the Folate Receptor Alpha (FRA).

26 Sep 2009

EMS provides free resources for protection against swine flu

Emergency Management & Safety Solutions (EMS), the crisis planner for many Fortune 100 companies, international government agencies and large non-profit organizations, is providing free resources to help people prepare for, prevent transmission of and take care of the ill to survive this wave of this year’s H1N1 flu pandemic. Today, over 180 countries have experienced the H1N1 virus outbreak and at least 3,486 people have died – including 1,000 Americans.

26 Sep 2009

Folotyn approved for the treatment of Peripheral T-Cell Lymphoma

The U.S. Food and Drug Administration has approved Folotyn (pralatrexate), the first treatment for a form of cancer known as Peripheral T-cell Lymphoma (PTCL), an often aggressive type of non-Hodgkins lymphoma.

25 Sep 2009

Phase 1b interim clinical trial results of IMO-2055, Tarceva and Avast combination announced

Idera Pharmaceuticals (Nasdaq: IDRA) today presented interim data from a phase 1b, single arm clinical trial evaluating IMO-2055, an agonist of Toll-like Receptor (TLR) 9, in combination with Tarceva® and Avastin® in patients with non-small cell lung cancer (NSCLC).

23 Sep 2009

Children’s Hospital offers tips on H1N1 and seasonal flu

With the early onset of flu season coinciding with the start of school this year, parents are concerned about the flu. Experts from The Children’s Hospital in Denver, Colo., offer a pediatric perspective on all types of flu, including H1N1, also known as swine flu.

23 Sep 2009

Bacterium responsible for outbreaks identified

University of Central Florida Microbiology Professor Keith Ireton has uncovered a previously unknown mechanism that plays an important role in the spread of a deadly food-borne bacterium.

22 Sep 2009

Study reveals that daily commuting may lead to mosquito-borne diseases

University of Hawaii at Manoa assistant researcher Durrell Kapan recently published a paper, Man Bites Mosquito: Understanding the Contribution of Human Movement to Vector-Borne Disease Dynamics, in PLoS One. Published August 26, the paper highlights how daily commuting patterns in mega-cities may be a critically overlooked factor in understanding the resurgence of mosquito-borne diseases such as dengue fever, infecting 50-100 million people annually.

21 Sep 2009

Research combining magnetism and nanotechnology

Researchers led by Daniel Kohane, MD, PhD of Children's Hospital Boston, funded by the National Institutes of Health, have devised a solution that combines magnetism with nanotechnology.

21 Sep 2009

Fully-insured members of Capital BlueCross to receive coverage for administration fee for H1N1 Flu vaccine

Capital BlueCross announced today that it will cover an administration fee for the H1N1 Flu vaccine for fully-insured members and those with individual coverage during the upcoming 2009-2010 flu season. Self-funded groups may opt to have their coverage customized to include this benefit.

17 Sep 2009

MDVIP's medical director suggests preventive measures for flu

Dr. Bernard Kaminetsky, the medical director of MDVIP, a national network of affiliated primary care doctors focused on preventive care, recommends, “Talk to your primary care physician now about the flu, both seasonal and H1N1 flu. Your primary care doctor is the one who can best prepare you for the upcoming season with vaccinations as well as information specific to you.”

16 Sep 2009

Four H1N1 vaccines approved by FDA

The U.S. Food and Drug Administration announced today that it has approved four vaccines against the 2009 H1N1 influenza virus. The vaccines will be distributed nationally after the initial lots become available, which is expected within the next four weeks.

16 Sep 2009

New data reveals the evolution of Immunoglobulin E

Immunoglobulin E (IgE) is the main actor in the drama of allergy. The biological role of IgE in the immune response of an organism and the lack of control leading to allergy is the research topic of Gernot Achatz, Molekular Biology, University of Salzburg. At the 2nd European Congress of Immunology ECI 2009 held in Berlin the scientist presents new data revealing the evolution of IgE.

15 Sep 2009

IBC offers coverage for H1N1 and seasonal flu vaccines

In an effort to help keep members healthy and flu-free this year, Independence Blue Cross (IBC) will offer coverage for the administration costs of the H1N1 (swine flu) vaccine when it becomes available. In addition, IBC will continue to cover seasonal flu vaccine.

15 Sep 2009

Nebulized interferon-gamma helps minimize transmissibility of TB

A new study published in the September 15, 2009, issue of PLoS ONE found that patients with cavitary pulmonary tuberculosis receiving anti-TB medications supplemented with nebulized interferon-gamma have fewer bacilli in the lungs and less inflammation, thereby reducing the transmissibility of tuberculosis in the early phase of treatment.

15 Sep 2009

Emergency Medical Associates to track swine flu movement with SAP business intelligence solutions

As families return from summer travels and children head back to school, Emergency Medical Associates (EMA) is preparing for a potential resurgence in the swine flu virus (H1N1) this fall. By using business intelligence (BI) solutions from SAP AG (NYSE: SAP), EMA will continue to pinpoint the movement of swine flu and alert federal organizations such as the Centers for Disease Control and Prevention (CDC) as well as 21 different emergency medical departments to patterns of outbreak.

14 Sep 2009

Malnutrition, poor sanitary conditions and HIV leads to defective immune system

The most common causes worldwide include malnutrition, poor sanitary conditions and human immune deficiency virus (HIV) infection. Other causes of temporary or permanent damage to the immune system include old age, medications (e.g. cortisone, cytostatic drugs), radiotherapy, stress after surgery and malignant tumors of the bone marrow and the lymph nodes.

14 Sep 2009

VBI's flu vaccine offers protection against H1N1

Variation Biotechnologies, Inc. (VBI), an emerging leader in the discovery and development of novel vaccines to fight infectious diseases, today reported that the company’s proprietary influenza vaccine triggered a robust immune response and provided protection against the H1N1 strain of influenza.

14 Sep 2009

Practical tips for parents on H1N1 and seasonal flu infections

With the early onset of flu season coinciding with the start of school this year, concern about the flu, and in particular the H1N1 strain of the flu, is growing among parents. Experts from The Children’s Hospital in Denver, Colo., can offer a pediatric perspective on all types of flu, including H1N1, also known as swine flu.

14 Sep 2009

NIH provides Inviragen second major grant to develop a dengue vaccine

Inviragen has received a $600,000 grant from the National Institute of Allergy and Infectious Diseases, part of the National Institutes of Health, to partially support its continued efforts to develop a safe and effective dengue vaccine. The two-year grant will fund a collaborative effort led by Inviragen and involving scientists at the University of Wisconsin and Division of Vector-Borne Infectious Diseases at the Centers for Disease Control and Prevention (CDC). The supported work will include additional optimization of Inviragen’s vaccine to generate more potent immune responses.

10 Sep 2009

Survey reveals that hand-washing behaviors are poor despite H1N1 swine flu

With the White House estimating that 30 to 50 percent of Americans will contract H1N1 flu this season, you’d think more people would be focused on prevention.

10 Sep 2009